ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Clinical Outcomes of Single-Dose Flomoxef Prophylaxis for Transrectal Prostate Biopsy: A Single-Center Study of 834 Cases.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProstate biopsy remains essential for the diagnosis of prostate cancer. Although the transperineal approach is increasingly favored, transrectal prostate biopsy (TRPB) continues to be performed in many institutions. In our institution, single-dose flomoxef (FMOX) was introduced as a prophylactic antibiotic in response to increasing resistance to levofloxacin (LVFX). This study evaluated the effectiveness and microbiological validity of FMOX using real-world clinical data.
methodsThis retrospective single-center study included 834 patients who underwent TRPB under single-dose intravenous FMOX (1 g) between 2015 and 2024. The clinical outcomes were acute prostatitis and sepsis within 4 weeks after biopsy. Post-biopsy bacteriuria was evaluated as an exploratory microbiological outcome. Pathogen distribution was described among patients with identified organisms, and factors associated with post-biopsy bacteriuria were evaluated using univariable analysis and multivariable logistic regressions.
resultsAmong 834 patients, prostatitis occurred in 0.5% of patients; no cases of sepsis were observed. Post-biopsy bacteriuria was observed in 6.5% of patients. Among 31 cases with identified pathogens, Enterococcus faecalis was the most common (54.8%), whereas Escherichia coli accounted for 12.9% of cases. Multivariable analysis identified prostate volume, International Prostate Symptom Score, and constipation as independent risk factors for post-biopsy bacteriuria.
conclusionsSingle-dose FMOX prophylaxis was associated with low rates of acute prostatitis and no cases of sepsis after TRPB. However, the absence of a comparator group and limitations in bacteriuria and culture assessment preclude definitive conclusions regarding its efficacy or microbiological impact. Further prospective comparative studies are needed to clarify the role of FMOX in TRPB prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.